Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Herman Chui

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 1, 2022
Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomasDara S Ross, Kelly A Devereaux, Cao Jin, et al.
Scientific Reports|January 20, 2022
Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancerSushmita B Gordhandas, Beryl Manning-Geist, Christina Henson, et al.
JCO Precision Oncology|September 27, 2021
Spectrum of <i>BRAF</i> Mutations and Gene Rearrangements in Ovarian Serous CarcinomaM Herman Chui, Jason C Chang, Yanming Zhang, et al.
Gynecologic Oncology|March 20, 2025
Anaplastic carcinoma of the ovary: A single-institution experience and molecular analysisMackenzie W Sullivan, M Herman Chui, Pier Selenica, et al.
The Journal of Pathology|November 28, 2023
Decreased HER2 expression in endometrial cancer following anti-HER2 therapyM Herman Chui, David N Brown, Arnaud Da Cruz Paula, et al.
Gynecologic Oncology|January 23, 2024
A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)Melissa Lumish, M Herman Chui, Qin Zhou, et al.
Molecular Oncology|July 20, 2024
ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability-high (MSI-H) molecular subtypeMelica Nourmoussavi Brodeur, Pier Selenica, Weining Ma, et al.
Gynecologic Oncology Reports|April 18, 2024
Molecular profiling of primary endometrioid endometrial cancer and matched lung metastases: <i>CTNNB1</i> mutation as a potential driverSushmita Gordhandas, Arnaud Da Cruz Paula, Elizabeth C Kertowidjojo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Clinicopathologic Features, Molecular Landscape, and Prognostic Implications of Ovarian Low-Grade Serous Tumors with Histologic TransformationM Herman Chui, Eun-Young Kang, Ryan M Kahn, et al.
Cancer|March 23, 2023
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapiesBeryl L Manning-Geist, Ryan M Kahn, David Nemirovsky, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 1, 2022
Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomasDara S Ross, Kelly A Devereaux, Cao Jin, et al.
Scientific Reports|January 20, 2022
Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancerSushmita B Gordhandas, Beryl Manning-Geist, Christina Henson, et al.
JCO Precision Oncology|September 27, 2021
Spectrum of <i>BRAF</i> Mutations and Gene Rearrangements in Ovarian Serous CarcinomaM Herman Chui, Jason C Chang, Yanming Zhang, et al.
Gynecologic Oncology|March 20, 2025
Anaplastic carcinoma of the ovary: A single-institution experience and molecular analysisMackenzie W Sullivan, M Herman Chui, Pier Selenica, et al.
The Journal of Pathology|November 28, 2023
Decreased HER2 expression in endometrial cancer following anti-HER2 therapyM Herman Chui, David N Brown, Arnaud Da Cruz Paula, et al.
Gynecologic Oncology|January 23, 2024
A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)Melissa Lumish, M Herman Chui, Qin Zhou, et al.
Molecular Oncology|July 20, 2024
ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability-high (MSI-H) molecular subtypeMelica Nourmoussavi Brodeur, Pier Selenica, Weining Ma, et al.
Gynecologic Oncology Reports|April 18, 2024
Molecular profiling of primary endometrioid endometrial cancer and matched lung metastases: <i>CTNNB1</i> mutation as a potential driverSushmita Gordhandas, Arnaud Da Cruz Paula, Elizabeth C Kertowidjojo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Clinicopathologic Features, Molecular Landscape, and Prognostic Implications of Ovarian Low-Grade Serous Tumors with Histologic TransformationM Herman Chui, Eun-Young Kang, Ryan M Kahn, et al.
Cancer|March 23, 2023
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapiesBeryl L Manning-Geist, Ryan M Kahn, David Nemirovsky, et al.
Pageof 5